Scientists have identified two specific types of brain cells that behave differently in people with depression, offering a ...

FDA commissioner Marty Makary told NBC News that the first psychedelic drug could be approved in the U.S. as soon as this ...

The federal government launched a behavioral health research initiative, with $50 million allocated to match state investments in psychedelic research, including psilocybin, a hallucinogenic compound ...

Most people know depression as a disorder of sadness. But for millions of patients, the most debilitating feature is ...

For centuries, healers knew what science is only now confirming: psilocybin is a powerful healing medicine. Could magic ...

COVID can take a physical toll. However, a family medicine physician from Baylor Scott and White in Temple explains how the ...

An experimental depression drug that joined the Neurocrine Biosciences pipeline as part of a broader package from Takeda Pharmaceutical failed to meet the main goal of a mid-stage clinical trial. The ...

Researchers found that 8.3% of US adults had at least one major depressive episode. In adolescents, the rate was 20.1%, with 29.2% of female adolescents reporting a major depressive episode. Major ...

More than 7 million people in the United States live with Alzheimer's disease and related dementia (ADRD). Some risk factors for ADRD, like genetics, can't be controlled, but others can be treated.

’Tis the season for recognizing seasonal affective disorder (SAD). Just don’t expect to find SAD in diagnostic handbooks. As a memorable term, SAD “stuck in the general public, and to some extent ...